Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.
Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Oncolytics Biotech Stock Down 1.4%
Shares of NASDAQ ONCY opened at $0.92 on Wednesday. The business's 50 day moving average is $1.00 and its two-hundred day moving average is $1.01. The company has a market cap of $106.26 million, a P/E ratio of -3.16 and a beta of 1.02. Oncolytics Biotech has a 12 month low of $0.33 and a 12 month high of $1.51.
Analyst Ratings Changes
Several brokerages have commented on ONCY. Weiss Ratings downgraded Oncolytics Biotech from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, April 24th. Wall Street Zen raised Oncolytics Biotech from a "strong sell" rating to a "hold" rating in a research report on Saturday, April 4th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Oncolytics Biotech presently has an average rating of "Moderate Buy" and an average target price of $8.50.
Read Our Latest Report on ONCY
Insider Transactions at Oncolytics Biotech
In other news, Director Wayne Pisano acquired 30,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were acquired at an average cost of $0.84 per share, for a total transaction of $25,200.00. Following the completion of the transaction, the director owned 492,414 shares in the company, valued at approximately $413,627.76. This trade represents a 6.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Bernd R. Seizinger acquired 40,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were purchased at an average price of $0.85 per share, for a total transaction of $34,000.00. Following the completion of the transaction, the director owned 566,991 shares of the company's stock, valued at $481,942.35. This trade represents a 7.59% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 304,282 shares of company stock valued at $259,232. Company insiders own 0.10% of the company's stock.
Institutional Trading of Oncolytics Biotech
A number of institutional investors and hedge funds have recently modified their holdings of the company. Scientech Research LLC bought a new stake in shares of Oncolytics Biotech during the third quarter valued at approximately $25,000. Blair William & Co. IL acquired a new stake in Oncolytics Biotech in the 4th quarter valued at $28,000. Security National Bank of Sioux City Iowa IA acquired a new stake in Oncolytics Biotech in the 4th quarter valued at $29,000. CIBC Private Wealth Group LLC acquired a new stake in Oncolytics Biotech in the 4th quarter valued at $44,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in Oncolytics Biotech in the 4th quarter valued at $63,000. 6.82% of the stock is currently owned by institutional investors.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc NASDAQ: ONCY is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company's lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.
Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
